Cell Medica granted Orphan Drug designation for novel cellular therapy
Advertisement
Cell Medica announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s cancer immunotherapy treatment, referred to as CMD-003, under development for Epstein-Barr virus (EBV) positive non-Hodgkin lymphomas. Additionally, the company announced the treatment of the first patient in the CITADEL Phase II clinical trial investigating the safety and efficacy of CMD-003 for the treatment of aggressive extranodal NK/T cell lymphoma (ENKTCL) in patients who have failed previous therapies. The patient was treated at the Dana-Farber Cancer Institute in Boston, MA under the care of Dr Eric Jacobsen.
Dr Jacobsen, clinical director of the adult lymphoma program at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, said: “Extranodal NK/T cell lymphoma can be a difficult disease to treat. Until recently there has been limited research devoted to this relatively rare disease. We are very excited to have treated the first patient in the CITADEL trial. Cytotoxic T cells are an exciting therapeutic area in oncology and I am hopeful that this approach will offer an effective new treatment option for these patients.”
CMD-003 is a novel way to target a range of cancers associated with the oncogenic Epstein-Barr Virus (EBV). The treatment has been developed by Cell Medica in collaboration with the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital. CMD-003 is produced from patient immune cells taken from a blood sample and sent to the Company’s manufacturing site for activation and expansion through a proprietary procedure developed for commercial-scale use. CAGT (Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital) has treated more than 250 patients with research prototypes of CMD-003 and has reported promising clinical results across a range of malignancies.
The CITADEL Trial will include NK/T cell lymphoma patients who have failed conventional treatment of advanced extranodal NK/T cell lymphoma. The trial will include patients recruited at 24 centers in five countries as part of clinical development programme aimed at regulatory approval in the USA, Europe and South Korea.
Other news from the department price development
Most read news
More news from our other portals
Last viewed contents
Drug costs vary by more than 600% in study of 10 high-income countries
Are the high prices of cancer drugs justified? - Does the cost correspond to the particular drug’s effectiveness in combating the disease?
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony - Vetter continues to expand in the US
A New Era Begins: BioSpring Builds High-Tech Manufacturing Facility for Pharmaceutical Nucleic Acid APIs
GEA invests EUR 80 million in a pharmaceutical technology center for freeze-drying systems in Germany - First product chambers in the “Factory of the Future”
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
ChatGPT grows insect-toxic genetically engineered plant - Blind spot in the EU draft law on genetic engineering
Commission launches new strategy to make Europe a global leader in life sciences by 2030
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech - BioNTech’s acquisition of CureVac will be implemented as planned
Time out: We all need a three-day weekend - Researchers confirm health benefits
Ibidi Awarded With the German bAV Prize 2023
